Equal performance of novel N-terminal proBNP (Cardiac proBNP®) and established BNP (Triage BNP®) point-of-care tests

Biomarkers in Medicine

Volumn 6, Issue 6, 2012, Pages 789-796

  Jungbauer, Carsten G ^a   Kaess, Bernhard ^a   Buchner, Stefan ^a   Birner, Christoph ^a   Lubnow, Matthias ^a   Resch, Markus ^a   Debl, Kurt ^a   Buesing, Monika ^a   Zerback, Rainer ^b   Riegger, Günter ^a   Luchner, Andreas ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

BNP; heart failure; natriuretic peptides; NT proBNP; POCT

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

ADULT; AORTA STENOSIS; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CLINICAL EXAMINATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPH; FEMALE; FLUID RETENTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERMETHOD COMPARISON; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

BLOOD CHEMICAL ANALYSIS; EDEMA, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POINT-OF-CARE SYSTEMS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84870870972     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.67     Document Type: Article

References (38)

1. Nielsen LS, Svangegaard J, Klitgaard NA, Egeblad H. N-Terminal pro-brain natriuretic peptide for discrimination between cardiac and non-cardiac dyspnoe. Eur. J. Heart Fail. 6, 63-70 (2004
2. Richards M, Nicholls MG, Espiner EA et al. Comparison of B-Type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J. Am. Coll. Cardiol. 47, 52-60 (2006
3. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-Terminal pro-brain natriuretic peptide (NTproBNP): A new marker of cardiac impairment. Clin. Endocrinol. 47, 287-296 (1997).
4. Hammerer-Lercher A, Ludwig W, Falkensammer G et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: Effects of assay on diagnostic performance of markers. Clin. Chem. 50, 1174-1183 (2004
5. Luchner A, Hengstenberg C, Löwel H et al. N-Terminal pro-brain natriuretic peptide after myocardial infarction: A marker of cardio-renal function. Hypertension 39, 99-104 (2002
6. Luchner A, Hengstenberg C, Löwel H et al. NTproBNP in outpatients after myocardial infarction: Interaction between symptoms and left ventricular function and optimized cut-points. J. Card. Fail. 11, S21-S27 (2005
7. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: Direct comparison of brain natriuretic peptide (BNP) and N-Terminal pro-BNP. Hypertension 46, 118-123 (2005
8. Jungbauer CG, Riedlinger J, Buchner S et al. High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-Terminal pro-B-Type natriuretic peptide. Clin. Chem. Lab. Med. 49(11), 1899-1906 (2011
9. Hall C. Essential biochemistry and physiology of (NTpro)BNP. Eur. J. Heart Fail. 6, 257-260 (2004
10. Mair J. Biochemistry of B-Type natriuretic peptide - where are we now? Clin. Chem. Lab. Med. 46, 1507-1514 (2008
11. Steiner J, Guglin M. BNP or NTproBNP? A clinician's perspective. Int. J. Cardiol. 129, 5-14 (2008
12. Buchner S, Jungbauer C, Birner C, Debl K, Riegger GA, Luchner A. Comparison of the cardiac markers B-Type natriuretic peptide and N-Terminal pro B-Type natriuretic peptide. Biomark. Med. 3, 465-481 (2009
13. Schäfer M, Bröker HJ, Luchner A et al. Diagnostic equivalence of an NTproBNP point-of-care test to the laboratory method in patients with heart failure and in reference populations. Point Care 9(2), 91-97 (2010
14. Zugck C, Nelles M, Katus HA et al. Multicentre evaluation of a new point-of-care test for the determination of NTproBNP in whole blood. Clin. Chem. Lab. Med. 44(10), 1269-1277 (2006
15. Hunt SA, Abraham WT, Chin MH et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53(15), E1-E90 (2009
16. Del Ry S, Giannessi D, Clerico A. Plasma brain natriuretic peptide measured by fully-Automated immunoassay and by immunoradiometric assay compared. Clin. Chem. Lab. Med. 39(5), 446-450 (2001
17. Shah K, Terracciano GJ, Jiang K, Maisel AS, Fitzgerald RL. Comparability of results between point-of-care and automated instruments to measure B-Type natriuretic peptide. West. J. Emerg. Med. 11, 44-48 (2010
18. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-Type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med. 350, 647-654 (2004
19. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130 (2000
20. Storti S, Prontera C, Emdin M et al. Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: Comparison with a point of care testing method. Clin. Chem. Lab. Med. 42, 1178-1185 (2004
21. Prontera C, Storti S, Emdin M et al. Comparison of a fully automated immunoassay with a point-of-care testing method for B-Type natriuretic peptide. Clin. Chem. 51, 1274-1276 (2005
22. Prontera C, Zaninotto M, Giovannini S et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-Terminal part of the propeptide of BNP (NTproBNP) immunoassays: The CardioOrmocheck study. Clin. Chem. Lab. Med. 47, 762-768 (2009
23. Maisel AS, Clopton P, Krishnaswamy P et al. Impact of age, race, and sex on the ability of B-Type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) multinational study. Am. Heart J. 147, 1078-1084 (2004
24. McCullough PA, Omland T, Maisel AS. B-Type natriuretic peptides: A diagnostic breakthrough for clinicians. Rev. Cardiovasc. Med. 4, 72-80 (2003
25. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-Type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347(3), 161-167 (2002
26. Januzzi JL Jr, Camargo CA, Anwaruddin S et al. The N-Terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 95, 948-954 (2005
27. Jørgensen B, Bertsch T, Bröker HJ et al. Multicentre evaluation of a second generation point-of-care assay with an extended range for the determination of N-Terminal pro-brain natriuretic peptide. Clin. Lab 58(5-6), 515-525 (2012
28. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 29(19), 2388-2442 (2008
29. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: Physiological role and clinical utility of cardiac natriuretic hormones. Am. J. Physiol. Heart Circ. Physiol. 301, H12-H20 (2011
30. Alibay Y, Beauchet A, El Mahmoud R et al. Plasma N-Terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. Biomed. Pharmacother. 59, 20-24 (2005
31. Alehagen U, Lindstedt G, Levin LA, Dahlström U. Risk of cardiovascular death in elderly patients with possible heart failure. B-Type natriuretic peptide (BNP) and the aminoterminal fragment of proBNP (N-Terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population. Int. J. Cardiol. 100, 125-133 (2005
32. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 91, 606-612 (2005
33. Sanz MP, Borque L, Rus A, Vicente B, Ramírez Y, Lasa L. Comparison of BNP and NTproBNP assays in the approach to the emergency diagnosis of acute dyspnea. J. Clin. Lab. Anal. 20, 227-232 (2006
34. McKie PM, Rodeheffer RJ, Cataliotti A et al. Amino-Terminal pro-B-Type natriuretic peptide and B-Type natriuretic peptide: Biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 47, 874-880 (2006
35. Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-Terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: A systematic review. Clin. Chem. 53, 813-822 (2007
36. Andreassi MG, Del Ry S, Palmieri C et al. Up-regulation of 'clearance' receptors in patients with chronic heart failure: A possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur. J. Heart Fail. 3, 407-414 (2001
37. Hystad ME, Oie E, Grogaard HK et al. Gene expression of natriuretic peptides and their receptors type-A and -C after myocardial infarction in rats. Scand. J. Clin. Lab. Invest. 61, 139-150 (2001
38. Vesely DL. Natriuretic peptides and acute renal failure. Am. J. Physiol. Renal Physiol. 285, 167-177 (2003